Stock Events

Stock Events

Nicox SA 

$0.3000
27
-$0.00-0% Wednesday 13:30

Statistics

Day High
0.44
Day Low
0.44
52W High
0.44
52W Low
0.25
Volume
100
Avg. Volume
0
Mkt Cap
26.53M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

2SepExpected
Q1 2024
Q3 2024
Q4 2024
Q1 2025
Q3 2025
Q1 2026
Next
-0.31
-0.17
-0.04
0.09
Expected EPS
N/A
Actual EPS
N/A

Financials

-62.29%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
21.48MRevenue
-13.38MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NICXF. It's not an investment recommendation.
Innate Pharma
6
IPH.PA
TotalEnergies
5
TTE.PA
Engie
5
ENGI.PA
Orange.
5
ORA.PA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, Inc. competes in the ophthalmology space with treatments for eye diseases, directly competing with Nicox's focus on eye health.
Novartis
NVS
Mkt Cap293.94B
Novartis AG, through its Alcon eye care division, offers products that compete in the same market as Nicox's eye health solutions.
Bausch Health Companies
BHC
Mkt Cap1.79B
Bausch Health Companies Inc., formerly Valeant Pharmaceuticals, has a significant presence in the eye health market, making it a direct competitor to Nicox.
Opko Health
OPK
Mkt Cap1.02B
OPKO Health, Inc. has a diversified portfolio that includes ophthalmology, competing with Nicox in the eye health sector.
EyePoint
EYPT
Mkt Cap1.2B
EyePoint Pharmaceuticals, Inc. focuses on developing treatments for eye diseases, directly competing with Nicox's product offerings.
Alcon
ALC
Mkt Cap33.07B
Alcon Inc. specializes in eye care products across surgery, vision care, and ophthalmology, competing with Nicox in the broader eye health market.
Regenxbio
RGNX
Mkt Cap721.18M
REGENXBIO Inc. is involved in the development of gene therapies for eye diseases, offering innovative treatments that compete with Nicox's solutions.
Staar Surgical
STAA
Mkt Cap1.38B
STAAR Surgical Company specializes in implantable lenses and other products for the eye, competing with Nicox in the surgical eye care market.

About

Nicox S.A., together with its subsidiaries, operates as an ophthalmology company in France and internationally. The company develops solutions to maintain vision and improve eye health. The company's lead product candidate is NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, which is in Phase 3 clinical trial. It also develops NCX 4251, a novel patented ophthalmic suspension of fluticasone propionate nanocrystals that is in Phase 2b clinical trial for the treatment of dry eye disease; and NCX 1728, a NO-donating phosphodiesterase-5 inhibitor, which is in preclinical evaluation. In addition, the company offers VYZULTA, a latanoprostene bunod ophthalmic solution to treat patients with open-angle glaucoma or ocular hypertension; and ZERVIATE, a cetirizine ophthalmic solution for the treatment of ocular itching related associated with allergic conjunctivitis. Nicox S.A. was founded in 1996 and is headquartered in Biot, France.
Show more...
CEO
Dr. Gavin M. Spencer
Employees
10
Country
France
ISIN
FR0013018124

Listings

STU
DE
NXOA.STU
MU
DE
NXOA.MU
LSE
GB
0RCQ.LSE
F
DE
NXOA.F

0 Comments

Share your thoughts

FAQ

What is Nicox SA stock price today?▼
The current price of NICXF is $0.30 USD — it has decreased by -0% in the past 24 hours. Watch Nicox SA stock price performance more closely on the chart.
What is Nicox SA stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Nicox SA stocks are traded under the ticker NICXF.
Is Nicox SA stock price growing?▼
NICXF stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Nicox SA has showed a +20% increase.
What is Nicox SA market cap?▼
Today Nicox SA has the market capitalization of 26.53M
When is the next Nicox SA earnings date?▼
Nicox SA is going to release the next earnings report on September 02, 2026.
What were Nicox SA earnings last quarter?▼
NICXF earnings for the last quarter are 0.09 USD per share, whereas the estimation was N/A USD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Nicox SA revenue for the last year?▼
Nicox SA revenue for the last year amounts to 21.48M USD.
What is Nicox SA net income for the last year?▼
NICXF net income for the last year is -13.38M USD.
How many employees does Nicox SA have?▼
As of July 15, 2026, the company has 10 employees.
In which sector is Nicox SA located?▼
Nicox SA operates in the Health & Wellness sector.
When did Nicox SA complete a stock split?▼
The last stock split for Nicox SA was on December 08, 2015 with a ratio of 1:5.
Where is Nicox SA headquartered?▼
Nicox SA is headquartered in Valbonne, France.